Should I Buy SGP? SGP 2026 Analysis

Should You Buy SpyGlass Pharma Inc (SGP) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

19.150

1 Day change

-1.64%

52 Week Range

32.440

Analysis Updated At

2026/06/19

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

SpyGlass Pharma Inc (SGP) is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators are mixed, with a neutral RSI and bearish moving averages. There are no significant trading trends, no recent news, and no positive catalysts to justify immediate investment. Additionally, the lack of financial performance data and analyst ratings makes it difficult to assess the company's growth potential. For now, holding off on investing in SGP is recommended until more favorable signals or data become available.

Technical Analysis

The MACD histogram is positive and expanding, indicating some bullish momentum. However, the RSI is neutral at 51.844, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 18.557, with resistance at 19.776 and support at 17.338.

Positive Catalysts

NULL identified. No recent news or significant trading trends from hedge funds or insiders.

Neutral/Negative Catalysts

Bearish moving averages and lack of recent news or trading activity from influential figures. No recent congress trading data.

Financial Performance

No financial data available for analysis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst ratings or price target changes available for review.

0 Analyst Rating

Wall Street analysts forecast SGP stock price to rise

0 Buy

0 Hold

0 Sell

Current: 19.470

Low

Averages

High

Current: 19.470

Low

Averages

High

H.C. Wainwright

Yi Chen

initiated

$37

AI Analysis

2026-03-10

Reason

H.C. Wainwright

Yi Chen

Price Target

$37

AI Analysis

2026-03-10

initiated

Reason

H.C. Wainwright analyst Yi Chen initiated coverage of SpyGlass Pharma with a Buy rating and $37 price target. SpyGlass is a clinical-stage biopharmaceutical company focused on the development of long-acting, sustained drug delivery of approved medicines, the analyst tells investors in a research note. The firm believes the company's bimatoprost solve the issue of patient non-compliance for prescribed topical medications, which could lead to better control of intraocular pressure.

Stifel

initiated

$42

2026-03-03

Reason

Stifel

Price Target

$42

2026-03-03

initiated

Reason

Stifel initiated coverage of SpyGlass Pharma with a Buy rating and $42 price target. The firm says that by combining a known drug, a known procedure, and a known device, SpyGlass' sustained-release drug-delivery BIM-IOL is "poised to capitalize on the ongoing interventional glaucoma secular shift." The BIM-IOL U.S. total addressable market is large at $13B annually, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SGP

Unlock Now

SGP Should I Buy

SGP Should I Buy

Should You Buy SpyGlass Pharma Inc (SGP) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch